Drug Discovery World

OCTOBER 5, 2023

This free 2-hour Summit will take place online and will outline areas of advancement and opportunity in the cancer research market. Find out the answer to questions such as: Where is the opportunity in the cancer research market? More to be announced. What are the best research tools to aid development of new treatments and vaccines?

Research 52

Research Antibody Medicine RNA 52

Pharmaceutical Technology

APRIL 27, 2023

GlobalData pharmaceutical analysts project that RNA-based gene therapies for oncology will grow from zero in 2022 to $4.6 Almost 20 years later, the benefits of SUT are well recognised in the manufacture of monoclonal antibodies and biopharmaceutical manufacturing in general. billion by 2028.

Manufacturing 130

Manufacturing RNA Contamination Vaccination 130

Drug Discovery World

OCTOBER 11, 2023

Experts and thought leaders in cancer research, precision medicine and immunotherapy will describe the latest research and the role of technology to help discover targets, develop cancer therapeutics and vaccines, and get to market faster.

Research 52

Research Antibody RNA Engineer 52

Roots Analysis

OCTOBER 13, 2023

As a result, in late nineties, the conjugation of drug with biological entities such as antibodies emerged as a possible solution for targeting earlier undruggable entities. However, it was not until 2000 when the first drug conjugate in the form of antibody drug conjugate (ADC) was approved by the USFDA.

Drugs 40

Drugs Antibody RNA Genetics 40

pharmaphorum

DECEMBER 13, 2021

One of its other scientific legacies was the specific development and approval of mRNA vaccines, the first in that drug class on the market. Since their launch, they have dominated the Covid-19 vaccine market due to their first-to-market status, efficacy and safety profiles and manufacturing success. It may have sold its 7.7%

RNA 94

RNA Vaccination Vaccine Development 94

pharmaphorum

JULY 6, 2021

Novartis has tried to get its marketing application for high cholesterol therapy inclisiran in the US back on track, after the FDA rejected it last year, by changing the factory that makes the drug.

RNA 99

RNA Manufacturing Sales Marketing 99

Drug Discovery World

MAY 13, 2024

Key to this is the ability to rapidly determine protein structures alone and in combination with antibodies or small molecules. This allows researchers to quickly view, for example, how many different antibodies are binding to a vaccine or virus. RA: How reliable are vaccines now for respiratory viruses such as flu?

Vaccination 59

Vaccination Vaccine Protein Antibody 59

pharmaphorum

JANUARY 7, 2022

billion licensing agreement with Ionis that gave it rights to eplontersen , a follow-up to Ionis’ already-marketed Tegsedi (inotersen) for polyneuropathy, another common complication of ATTR. The new agreement comes just days after AZ closed a $3.1 billion on the first nine months of 2021, well ahead of Pfizer’s own forecasts.

Antibody 113

Antibody Licensing Licensing Protein 113

Drug Discovery World

NOVEMBER 15, 2022

Applications: The ability to synthesise longer, accurate DNA sequences opens up a vast array of application possibilities: generating CRISPR libraries, in situ hybridisation probes, antibody libraries, vaccines, and so on, along with the ability to engineer metabolic pathways, microbes, and plants. .

DNA 98

DNA Drugs Antibody Engineer 98

Drug Discovery World

NOVEMBER 30, 2023

The company’s goal is to accelerate functional characterisation and shortenoptimisation time in antibody discovery and t-cell workflows. It was presented by Xiaole Shirley Liu, PhD, CEO, GV20 Therapeutics, and titled: ‘AI-based target and antibody discovery from patient tumour profiles’.

Antibody 59

Antibody Protein Engineer In-Vivo 59

pharmaphorum

DECEMBER 23, 2021

Novartis resubmitted its marketing application in the US earlier this year, after swapping fill-and-finish production to one of its own facilities in Schaftenau, Austria. Third-quarter sales of Leqvio were just $5 million, although that will reflect the lag between regulatory approval and reimbursement negotiations in European markets.

Drugs 97

Drugs Sales Antibody FDA Approval 97

Drug Discovery World

NOVEMBER 13, 2023

Ahead of protein and antibody engineering conference PEGS Europe 2024 in Lisbon, DDW’s Megan Thomas looks at what to expect from each track of the annual biologics technology meeting. Hiroki Shirai, PhD, Coordinator, RIKEN Center for Computational Science, on: ‘Applying deep learning anomaly detection to antibody structures’.

Protein 59

Protein Antibody Engineer Scientist 59

Roots Analysis

MAY 21, 2024

Gene Therapies: LNPs have the ability to effectively deliver nucleic acids, including small interfering RNA (siRNA), messenger RNA (mRNA), and plasmid DNA to the target cells. Further, they have been extensively utilized in the development of mRNA vaccines for COVID-19.

Drug Delivery 40

Drug Delivery Drugs Gene Therapy Bioavailability 40

Roots Analysis

DECEMBER 12, 2023

As a result, innovators came up with the idea of magic bullets, antibody drug conjugates (ADCs). It is comprised of three components, namely antibody, drug and linker. The antibody is conjugated to the drug via a linker molecule. The antibody is conjugated to the drug via a linker molecule. Components of an ADC?

Antibody 40

Antibody Manufacturing Drugs RNA 40

pharmaphorum

DECEMBER 1, 2020

The filing for a conditional marketing authorisation completed the rolling submission process that began on October 6. The EMA has also confirmed it has received a filing from Moderna, which is producing a rival vaccine based on similar RNA technology.

Vaccination 66

Vaccination Vaccine RNA Clinical Trials 66

Worldwide Clinical Trials

MAY 30, 2024

Since marketing authorization for the first breakthrough treatment in 1994, the steady increase in clinical trials reflects the community’s commitment to finding effective ALS treatments despite the numerous hurdles associated with clinical trial design, from proof-of-concept to pivotal trials. Director, Therapeutic Area Medical Lead.

Gene 162

Gene Clinical Trials Clinical Trials Gene Therapy 162

XTalks

OCTOBER 26, 2023

variant was selected in June and within a few months, both Pfizer-BioNTech and Moderna were able to get vaccines for it to market by September, which Dr. Kierstead says is “astonishingly fast.” The Flu versus COVID-19: Virology and Vaccines SARS-CoV-2 versus Influenza Virology Viruses contain genetic material that can either be RNA or DNA.

Vaccination 105

Vaccination Vaccine RNA Manufacturing 105

pharmaphorum

MARCH 9, 2022

Sanofi and Sobi’s haemophilia partnership has been under competitive pressure from new therapies like Roche’s antibody Hemlibra, so the two companies are hoping a new long-acting drug candidate can revitalise the franchise. The half life of the new drug – one of the main draws for Sanofi’s $11.6

Sales 94

Sales Protein Gene Therapy Regulation 94

The Pharma Data

DECEMBER 8, 2020

Since partnering with Eli Lilly to produce the first monoclonal antibody therapy approved for mild-to-moderate COVID-19 patients, antibody discovery company AbCellera is going big on the Nasdaq. Cornering the untapped Chinese CNS market, SciNeuro launched with $100 million in their pocket. Reduce cost. Nuance Pharma .

RNA 52

RNA Antibody Life Science Protein 52

pharmaphorum

APRIL 5, 2022

.” Strong efficacy data is likely to be the key to carving out a role for the antisense drug in the PCSK9 inhibitor class, particularly as it is up against some heavyweight competition – notably Novartis’ small interfering RNA (siRNA) therapy Leqvio (inclisiran), which only needs to be administered twice a year.

Drugs 52

Drugs Antibody Sales FDA Approval 52

pharmaphorum

FEBRUARY 9, 2021

InteRNA is focusing on the development of gene-silencing drugs based on microRNA, naturally occurring, non-coding strands of RNA that are thought to regulate gene expression in cells. The major difference between siRNAs and microRNAs is that the former are very specific to one messenger RNA target, while the latter can have multiple targets.

Trials 57

Trials Gene Silencing RNA Gene Expression 57

XTalks

JUNE 5, 2023

In February 2023, Pfizer revealed that the European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA) for Abrysvo. RSV belongs to the family of negative-strand RNA viruses and was first identified in 1955. The global RSV vaccine and antibody market is expected to reach $2.56

Vaccination 98

Vaccination Vaccine FDA Approval Protein 98

pharmaphorum

JULY 19, 2021

A new report published by Medicines Discovery Catapult and CPI details the huge medical and market potential for complex medicines in the UK. The market value for complex medicines is set to reach hundreds of billions of pounds, and you can see why with the potential benefits for patients.”.

Life Science 52

Life Science Medicine RNA Vaccination 52

pharmaphorum

JANUARY 5, 2022

The results of the CORAL-BOOST are only in a few patients, but showed strong increases in neutralising antibody levels when Gritstone’s shot given as a booster after two doses of AstraZeneca’s Vaxzevria given as a primary course. “With new variants – like Omicron and B.1.640.2

Protein 114

Protein Vaccination Vaccine Immune Response 114

Roots Analysis

DECEMBER 18, 2023

This novel modality emerged when pharmaceutical developers used non-antibody-based entities as targeting ligand to develop targeted therapeutics. Similar to the structure of the antibody drug conjugates, these next generation drug conjugates use a non-antibody-based targeting ligand, a cytotoxic payload and a linker.

Drugs 40

Drugs FDA Approval Antibody Development 40

pharmaphorum

DECEMBER 21, 2020

Inclisiran is a small interfering RNA (siRNA) therapy that works by inhibiting PCSK9 – the same target as Amgen’s Repatha (evolocumab) and Sanofi/Regeneron’s Repatha (alirocumab) – but is dosed only twice a year rather than every month. Payers had deemed the drugs to be too expensive and even price cuts failed to expand their use.

Drugs 52

Drugs RNA Manufacturing Licensing 52

pharmaphorum

JULY 13, 2022

The first to reach the market were antibodies – Amgen’s Repatha (evolocumab) and Sanofi/Regeneron’s Praluent (alirocumab) – which reached the market several years ago. They are administered every two to four weeks, depending on LDL cholesterol response.

Gene Editing 97

Gene Editing Trials Drugs Gene 97

Roots Analysis

JANUARY 24, 2024

Presently, close to 60 manufacturers have adopted end to end continuous manufacturing and semi-continuous manufacturing process for various types of biologics, including antibodies, enzymes, proteins / peptides, vaccines and viral vectors. Such developments will support the continuous manufacturing market growth.

Manufacturing 40

Manufacturing Contract Manufacturing Production Marketing 40

The Pharma Data

JUNE 26, 2021

The open-label randomized trial evaluates the efficacy, tolerability, and safety of BNT111 in combination with Libtayo, an anti-PD-1 monoclonal antibody, being co-developed by Regeneron and Sanofi. These results were published in Nature in July 2020. About FixVac.

Clinical Trials 52

Clinical Trials Clinical Trials Trials Immune Response 52

Drug Discovery World

OCTOBER 16, 2023

A company within this ecosystem is STORM Therapeutics, a clinical stage biotechnology company creating novel small molecule therapies that inhibit RNA modifying enzymes (RME) for use in oncology and other diseases.

Drugs 75

Drugs Life Science Gene Therapy Genome 75

Pharmaceutical Technology

APRIL 24, 2023

Since then, the field of nanomedicine has steadily progressed to reach high points such as the successful use of nanotechnology to deliver messenger RNA (mRNA)-based Covid-19 vaccines. This design protects antibodies from the innate immune system. And the issue is that antibodies are too big to go directly inside the cell,” he says.

Drug Delivery 147

Drug Delivery Vaccination Vaccine Research 147

The Pharma Data

MAY 3, 2021

Pfizer reported that it submitted its application for extension of authorization last week, and EMA announced today that it has undertaken the evaluation of the messenger RNA (mRNA) vaccine. Pfizer also shared antibody responses from the younger age group.

Vaccination 52

Vaccination Vaccine Antibody RNA 52

pharmaphorum

NOVEMBER 17, 2020

Both Pfizer and Moderna vaccines use synthetic messenger RNA to activate the immune system against the virus. They both code for the “Spike” protein seen on the surface of the SARS-CoV-2 coronavirus, which causes the body to produce antibodies that neutralise the virus in the event of an infection.

Vaccination 64

Vaccination Vaccine RNA Clinical Trials 64

Drug Discovery World

MARCH 13, 2024

According to Statista, revenue in this sector is expected to grow at an annual rate of 6.77%, resulting in a market volume of US$2,208m by 2028 1. In 2022, Boehringer Ingelheim bought exclusive worldwide rights to research, develop and commercialise products based on a panel of innovative, tumour- specific antibodies from A*STAR.

Life Science 69

Life Science Genome Genomics Research 69

pharmaphorum

JULY 11, 2022

Sanofi R&D in its core haemophilia category is advancing on three fronts – engineered proteins, RNA interference drugs and gene therapies – and highlighted results in two of those at the International Society on Thrombosis and Haemostasis (ISTH) congress over the weekend. Sanofi acquired the drug when it bought Bioverativ in 2018 for $11.6

Engineer 52

Engineer Sales Gene Therapy Drugs 52

pharmaphorum

MARCH 1, 2021

COVID-19 antigen tests diagnose active infection by detecting SARS-CoV-2 viral proteins in samples, as opposed to PCR tests which detect viral RNA and require lab processing, but can miss infections with low virus levels.

In-Vitro 98

In-Vitro RNA Protein Antibody 98

pharmaphorum

JULY 21, 2021

Leqvio – acquired via Novartis’ near $10 billion acquisition of the Medicine Company in 2019 – is already approved in Europe but getting it on the US market is central to Novartis’ hopes of blockbuster sales for the product.

Sales 52

Sales Gene Therapy RNA Production 52